Domainex and UCB Complete First Collaborative Project
News Jul 19, 2007
Domainex used its Combinatorial Domain Hunting technology to identify a soluble and highly-expressed construct of a protein that had been refractory to other methods. This construct was then used by UCB to obtain a high-resolution crystal structure of the target protein with a proprietary inhibitor bound to the active site.
Mark Bushfield of UCB commented: "The construct provided by Domainex has all the characteristics that we were looking for, and I am sure this would not have been found using any other method. We are currently in discussions to agree the next stage of our collaboration".
Eddy Littler, CEO of Domainex, added: "Our technology is unique, proprietary and offers an opportunity to work on targets hitherto unavailable to the pharmaceutical industry. We are delighted that our collaboration with UCB has already come to fruition and we look forward to working together on future projects."
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE
DNA Methylation Related to Liver Disease in Obese PatientsNews
DNA methylation implicated in initiation of liver fibrosis in non-alcoholic fatty liver diseaseREAD MORE
UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPONews
MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018